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A B S T R A C T
Purpose
The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone)
with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM
(rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial
therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with amedian
follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end
point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio
in terms of toxicity than R-FM. We report a post hoc analysis of this trial after a median follow-up of
7 years.
Patients and Methods
Of the 534 enrolled patients, 504 were evaluable. At the time of analysis, the median follow-up was
84 months (range, 1 to 119 months).
Results
The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to
49%) and 48% (95% CI, 43% to 53%), respectively. The hazard ratio for progression-free survival
adjusted by FL International Prognostic Index 2 versus R-CVP was 0.73 for R-CHOP (95%CI, 0.54 to
0.98; P = .037) and 0.67 for R-FM (95% CI, 0.50 to 0.91; P = .009). The 8-year overall survival (OS)
rate was 83% (95%CI, 79% to 87%), with no significant differences among study arms. Overall, we
observed a higher risk of dying as a result of causes unrelated to lymphoma progression with R-FM
versus R-CVP.
Conclusion
With an 83%8-year OS rate, long-term follow-up of the FOLL05 trial confirms the favorable outcome
of patients with advanced-stage FL treated with immunochemotherapy. The three study arms had
similar OS but different activity and toxicity profiles. Patients initially treated with R-CVP had a higher
risk of lymphoma progression compared with those receiving R-CHOP, as well as a higher risk of
requiring additional therapy.
J Clin Oncol 35. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Follicular lymphoma (FL) is the most common of
the indolent non-Hodgkin lymphomas (NHLs)
and constitutes approximately 10% to 20% of all
newly diagnosed NHLs in Western countries.1
The natural history of FL is that of a low-grade
lymphoma, with the typical pattern of relapses
after initial therapy followed by remissions of
increasingly shorter duration after each event
and by the risk of transformation into aggressive
lymphoma.2 With the availability of anti-CD20
monoclonal antibody, the outcome for patients
with FL has greatly improved, and sequential
treatment with active immunochemotherapy (ICT)
regimens is associated with high response rates
and prolonged survival.3 Patients with FL now
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show remission rates of nearly 90%, a median progression-free
survival (PFS) of 6 to 7 years, and 5-year overall survival (OS) rates
approaching 90%.4-6
Although the use of anti-CD20 monoclonal antibody is
confirmed by strong evidence, choice of chemotherapy backbone
has been a matter of debate for many years and is still made based
on limited evidence. In 2005, the Fondazione Italiana Linfomi
initiated the randomized FOLL05 trial to identify the best ICT
regimen for first-line treatment of advanced-stage FL among R-CVP
(rituximab plus cyclophosphamide, vincristine, and prednisone),
R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vin-
cristine, and prednisone), and R-FM (rituximab plus fludarabine
and mitoxantrone). In 2013, we published the primary analysis of
the study, with a median follow-up of 34 months, showing the
superiority of R-CHOP and R-FM over R-CVP in terms of time to
treatment failure (TTF) and PFS, but our results also revealed a better
toxicity profile for R-CHOP compared with R-FM.7 Overall, these
data were interpreted to suggest R-CHOP as the standard ICT for the
treatment of patients with advanced-stage FL.
The use of early end points as surrogates of OS is accepted by
the scientific community and enables clinical trials of indolent
disease. However, the long natural history of FL warrants a long-
term update of clinical trials to better evaluate the risk-benefit ratio
of treatment. Here, we present an analysis of the mature results of
the FOLL05 trial after a median follow-up of 7 years.
PATIENTS AND METHODS
Patients
FOLL05 was a prospective, randomized, open-label, multicenter
phase III trial that included previously untreated patients with advanced-
stage symptomatic FL. Eligible patients had a histologically confirmed
diagnosis of grade 1, 2, or 3a FL according to the 2008WHO classification,8
had Ann Arbor stage II to IV disease, were age 18 to 75 years with Eastern
Cooperative Oncology Group performance status of 0 to 2, and had active
disease according to Italian Society of Hematology guidelines.9 Exclusion
criteria included a diagnosis of grade 3b FL, evidence of histologic
transformation into an aggressive lymphoma at the time of diagnosis, CNS
involvement, or history of previous malignancy.
This study was conducted in compliance with the Declaration of
Helsinki and in accordance with Good Clinical Practice rules and was
approved by a research ethics committee. All enrolled patients provided
written informed consent. Patients were randomly assigned to receive eight
doses of rituximab combined with eight courses of CVP (arm A [R-CVP]),
six cycles of CHOP (arm B [R-CHOP]), or six cycles of FM (arm C
[R-FM]). Because its cost was not reimbursed in 2005, maintenance was
not admitted and was considered to be failure for the primary study end
point if administered.
Response was assessed with clinical examination, contrast-
enhanced computed tomography, and bone marrow biopsy if required.
[18F]fluorodeoxyglucose positron emission tomography was not
mandatory for response assessment but was performed in a significant
proportion of patient cases.10 When available, [18F]fluorodeoxyglucose
positron emission tomography was not considered for staging or definition
of response. Clinical examination of patients who completed treatment
was planned every 3 months for the first 6 months, every 6 months for
3 years, and then annually. Computed tomography scans were performed
every 6 months for 2 years, then annually or when clinically indicated.
Follow-up updates were actively conducted among participating in-
stitutions. Relapses or progressions were determined based on clinical or
radiologic assessment.
Statistical Methods
In addition to TTF, the primary study end point, this long-term
analysis was conducted to evaluate PFS, OS, cause-specific mortality
(CSM), cumulative incidence of second malignancies (SMs), and fre-
quency of late adverse events. For this analysis, the initial definition of
sample size was not applicable; the analysis was conducted as a post hoc
long-term observational study of patients enrolled in the FOLL05 trial.
Molecular response was also included as a secondary end point and results
published in a separate report.11
TTF was defined as the time from random assignment to discon-
tinuation of treatment of any reason, including disease progression,
treatment toxicity, start of maintenance therapy, or death. PFSwas defined as
the time from random assignment to progressive disease or death resulting
from any cause. OS was calculated as the time from patient random
assignment to death resulting from any cause. Adverse events were registered
in accordance with the standard Common Toxicity Criteria for Adverse
Events (version 3).
For the analysis of CSM, cause of death was described as reported by
the local investigator and classified as lymphoma related in the case of
documented uncontrolled progression of lymphoma or non–lymphoma
related (NLR) in patients who died as a result of causes not directly related
to lymphoma progression. NLR events were additionally classified as
resulting from SMs or other causes. Death resulting from SM was con-
sidered in the case of death directly associated with the presence of an
uncontrolled and/or progressive SMor occurring during treatment for SM;
death resulting from causes other than lymphoma progression or SM was
classified as resulting from other causes.
Survival curves were calculated using the Kaplan-Meier method and
compared using the log-rank test. Effect sizes were reported as hazard
ratios (HRs) with 95% CIs and estimated using the Cox proportional
hazards regression method, adjusted by relevant confounding factors when
needed. Risk of SM was reported as a cumulative incidence function, with
death as a competing risk, using the method of Gooley et al12; comparisons
between curves were performed using the Gray test13 and Fine-Gray re-
gression.14 The cumulative risk of histologic transformation and CSM was
reported according to the Nelson-Aalen estimator. For the purposes of this
study, only biopsy-proven histologic transformations were considered.
All reported tests were two sided, and P , .05 was considered to
indicate moderate strength of evidence against the null hypothesis. P values
were not adjusted for multiple comparisons. The analysis was performed
according to the intention-to-treat (ITT) approach, except for studies
involving SMs and late adverse events, which were analyzed according to
actual therapy received.
RESULTS
FromMarch 2006 to September 2010, 534 patients were enrolled in
the FOLL05 trial by 58 Italian institutions; of these patients, 504
were eligible for ITT analysis (Fig 1). The main characteristics of
eligible patients, whose median age was 55 years (range, 30 to
75 years), were described in the original report.7
The median follow-up was 84 months (range, 1 to 119 months).
Overall, 43 patients were lost to follow-up (8.5%) after a median
time of 64 months (range, 1 to 101 months). Minimum follow-up
for surviving patients not lost to follow-up was 4.5 years. With
prolonged follow-up, the 8-year TTF was 44% (95% CI, 39% to
49%). R-CHOP and R-FM had better TTF rates than R-CVP: 45%
(HR, 0.73; 95% CI, 0.55 to 0.98; P = .033) and 49% (HR, 0.70;
95% CI, 0.52 to 0.93; P = .016) versus 38% at 8 years, respectively
(Fig 2A).
Overall, 252 events were recorded for PFS, including 68 addi-
tional episodes compared with the initial report (five progressions,
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58 relapses, and five deaths not related to lymphoma progression;
Table 1). The 8-year PFS rate was 48% (95% CI, 43% to 52%); for
patients randomized to the R-CVP, R-CHOP, and R-FM arms, it
was 42% (95%CI, 35% to 50%), 49% (95% CI, 40% to 57%), and
52% (95% CI, 45% to 60%), respectively (Fig 2B). Considering
PFS adjusted by the FL International Prognostic Index 2, the HRs
between R-CHOP versus R-CVP and R-FM versus R-CVP were
0.73 (95% CI, 0.54 to 0.98; P = .037) and 0.67 (95% CI, 0.50 to
0.91; P = .009).
Salvage Therapy
Overall, 208 of 248 patients who had primary refractory or
experienced progressive or relapsed disease required salvage
treatment: 90 received conventional ICT, 75 underwent autologous
stem-cell transplantation (ASCT), 33 were treated with immu-
notherapy alone, and 10 were treated with radiotherapy alone
(Table 2).
Among the 75 patients who underwent ASCT, a similar
distribution by study arm was observed (n = 27, 27, and 21 for
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Fig 2. (A) Time to treatment failure (TTF;
R-CHOP [rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone] v R-CVP
[rituximab plus cyclophosphamide, vincristine,
and prednisone]: P = .033; R-FM [rituximab plus
fludarabine andmitoxantrone] vR-CVP:P= .016)
and (B) progression-free survival (PFS) by treat-
ment arm (R-CHOP v R-CVP adjusted by Fol-
licular Lymphoma International Prognostic Index
2 [FLIPI-2]: P = .037; R-FM v R-CVP adjusted by
FLIPI-2: P = .009).
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R-CVP, R-CHOP, and R-FM, respectively). Overall, patients ini-
tially randomly assigned to R-CVP were at higher risk for requiring
a second-line therapy (91 patients [55%]), compared with those
receiving R-CHOP (n= 63 [38%]) or R-FM (n= 54 [32%]; P, .001).
Patients treated with R-CVP had 43% higher probability of re-
quiring salvage therapy versus those receiving R-CHOP.
SMs
During follow-up, 41 SMs were reported: 14 were hematologic
and 27 were solid cancers. Twenty-one SMs were diagnosed in
patients who never experience relapse and never received salvage
therapy (n = 1, 10, and 10 for R-CVP, R-CHOP, and R-FM, re-
spectively; Table 3). The cumulative incidence of SMs at 8 years was
9.4% (95% CI, 6.8% to 13.0%), and the median time to SM
development was 33 months (range, 8 to 96 months). The cu-
mulative incidence by actual treatment at 8 years was 6.2% (95%
CI, 2.5% to 14.8%), 12% (95% CI, 7.7% to 18.7%), and 9.6%
(95% CI, 6.0% to 15.2%) for R-CVP, R-CHOP, and R-FM, re-
spectively (Gray test P = .077). The HRs for SMs between R-CHOP
and R-CVP and between R-FM and R-CVP were 2.59 (95% CI,
1.09 to 6.20; P = .032) and 2.29 (95% CI, 0.94 to 5.56; P = .067),
Table 1. PFS-Defining Events and Causes of Death by Treatment Arm
Event
ITT
Total
R-CVP
(n = 168)
R-CHOP
(n = 165)
R-FM
(n = 171)
Early Update Total Early Update Total Early Update Total
PFS
Progression 3 — 3 4 — 4 6 — 6 13
Progression after SD 7 2 9 2 1 3 2 2 4 16
Relapse from CR/PR 64 16 80 44 25 69 44 17 61 210
Death resulting from any cause — 2 2 2 2 4 6 1 7 13
Total 74 20 94 52 28 80 58 20 78 252
Cause of death
FL progression 4 13 17 6 8 14 8 7 15 46
SM — 1 1 1 3 4 4 3 7 12
Cardiopathy — 1 1 1 1 2 2 — 2 5
Sepsis — — — — 1 1 2 1 3 4
GVHD liver — — — — — — — 1 1 1
Cachexia — — — 1 — 1 — — — 1
Car accident — — — 1 — 1 — — — 1
Hemorrhage — — — — — — 1 — 1 1
Intestinal infarction — — — — — — — 1 1 1
Unknown — 2 2 — — — — 1 1 1
Total 4 17 21 10 13 23 17 14 31 75
Abbreviations: CR, complete remission; FL, follicular lymphoma; GVHD, graft-versus-host disease; ITT, intention to treat; PFS, progression-free survival; PR, partial
remission; SD, stable disease; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus cyclophosphamide, vin-
cristine, and prednisone; R-FM, rituximab plus fludarabine and mitoxantrone; SM, second malignancy.
Table 2. Details of Salvage Therapies Prescribed After First Relapse or Progression of FL
Second Line
No. (%)
ITT
Total
(n = 504)
R-CVP
(n = 165)
R-CHOP
(n = 166)
R-FM
(n = 171)
Stable CR/PR 67 (41) 84 (51) 88 (51) 239 (47)
Death in CR/PR or lost to follow-up 3 (2) 4 (2) 10 (6) 17 (3)
Second-line treatment 91 (55) 63 (38) 54 (32) 208 (41)
Immunochemotherapy 44 (27) 19 (11) 27 (16) 90 (18)
R-CHOP 6 RT 26 (16) — 15 (9) 41 (8)
Rituximab + fludarabine 9 (6) 5 (3) 1 (1) 15 (3)
Rituximab + bendamustine 5 (3) 13 (8) 5 (3) 23 (5)
Rituximab + other 4 (2) 1 (1) 6 (4) 11 (2)
HDT 27 (16) 27 (16) 21 (12) 75 (15)
Immunotherapy 16 (10) 13 (8) 4 (2) 33 (7)
Radiotherapy 4 (2) 4 (2) 2 (1) 10 (2)
None/watch and wait 3 (2) 5 (3) 10 (6) 18 (4)
Not available 4 (2) 9 (5) 9 (5) 22 (4)
NOTE. Percentages refer to all patients, not only to those with relapsed disease.
Abbreviations: CR, complete remission; FL, follicular lymphoma; ITT, intention to treat; PR, partial remission; HDT, high-dose therapy; R-CHOP, rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine, and prednisone; R-FM, rituximab plus fludarabine
and mitoxantrone; RT, radiotherapy.
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respectively. At time of relapse, 81 of 210 patients had undergone
biopsy; histologic transformation was documented and biopsy
confirmed in 11 patients, with a 2.9% (95% CI, 1.5% to 5.5%)
cumulative incidence at 8 years (Table 3).
OS
Overall, 75 deaths were reported: 21, 23, and 31 in the R-CVP,
R-CHOP, and R-FM arms, respectively. The 8-year OS rate was
83% (95% CI, 78% to 86%); by ITT analysis, it was 85% (95% CI,
77% to 91%), 83% (95% CI, 75% to 89%), and 79% (95%CI, 71%
to 85%) for R-CVP, R-CHOP, and R-FM, respectively (P = .243;
Fig 3).
Forty-six deaths (61%) resulted from lymphoma progression,
and 29 (39%) resulted from other causes (Table 1). None of the
fatal infectious events occurred during induction therapy or in
patients who never experienced relapse. The risk of death resulting
from lymphoma was comparable among study arms (P = .900),
whereas the risk of death resulting fromNLR causes was higher with
R-FM (11.2% at 8 years) thanwith R-CVP (1.8%; P= .005); the NLR
CSM difference between R-CVP and R-CHOP (6.4% for R-CHOP)
was not statistically significant (P = .157; Figs 4A and 4B). Of the
12 deaths resulting from SMs, sevenwere reported in the R-FM arm,
four in the R-CHOP arm, and one in the R-CVP arm (Table 3); in
the only patient treated with R-CVP and in one patient treated with
R-CHOP, an SMwas diagnosed after salvage ASCT. The CSM curves
by SMs and by other causes are provided in Figures 4C and 4D.
DISCUSSION
With our long-term analysis of the FOLL05 trial, we provide new
and more detailed data on the randomized comparison among
R-CVP, R-CHOP, and R-FM. Overall, the observed 8-year OS rate
of 84% clearly shows that the natural history of patients with FL has
improved compared with the past. In addition, a significant pro-
portion of patients (48% in this study) were still free from lym-
phoma progression 8 years after initial diagnosis, and at least in some
patients, this result may translate into a possible cure of lymphoma.
Although the study was not originally powered for OS analysis, no
differences were observed for OS among the three study arms;
however, this result was achieved with the need for second-line
therapy in one of four patients treated with R-CVP versus those
randomly assigned to R-CHOP and at the cost of higher mortality
Table 3. SMs by Treatment Arm for All Patients in FOLL05 Trial and for Those Without Relapsed Disease or Salvage Therapy
SM
Actual Treatment
No Relapse or Salvage Therapy All Patients in Study
R-CVP
(n = 69)
R-CHOP
(n = 87)
R-FM
(n = 98)
Total
(n = 254)
R-CVP
(n = 165)
R-CHOP
(n = 166)
R-FM
(n = 171)
Total
(n = 502)
Breast cancer (female) — 1 — 1 1 2 1 4
Uterine cancer — 1 2 (1*) 3 (1*) — 1 2 (1*) 3 (1*)
Prostate cancer — 1 1 2 2 1 1 4
Lung cancer — 2 (1*) 1* 3 (2*) — 2 (1*) 1* 3 (2*)
Kaposi sarcoma/skin cancer — — 1 1 1 1 2 4
GI tract — 1 — 1 1 1 1* 3 (1*)
Urothelial cancer — 2 — 2 — 2 — 2
Pancreatic cancer — — — — — — 1* 1*
Melanoma 1 — 1 2 1 — 1 2
Glioblastoma — 1* — 1* — 1* — 1*
AML/MDS — 1 3 (2*) 5 (2*) 1* 3 (2*) 5 (3*) 9 (6*)
Hodgkin lymphoma — — 1 1 — 1 1 2
Multiple myeloma — — — — — 1 — 1
CLL — — — — — 1 — 1
SMZL — — — — — 1 — 1
Total 1 10 (2*) 10 (4*) 21 (6*) 7 (1*) 18 (4*) 16 (7*) 41 (12*)
Histologic transformation — — — — 5 (2*) 4 (3*) 2 11 (5*)
Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic lymphoma; MDS, myelodysplastic syndrome; R-CHOP, rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine, and prednisone; R-FM, rituximab plus fludarabine and mitoxantrone; SM,
second malignancy; SMZL, spleen marginal zone lymphoma.
*Indicates patients who have died (Nos. in brackets indicate deaths).
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Fig 3. Overall survival (OS) by treatment arm according to intention-to-treat
analysis (R-CVP [rituximab plus cyclophosphamide, vincristine, and prednisone]
v R-CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine, and predni-
sone] v R-FM [rituximab plus fludarabine and mitoxantrone]: log-rank P = .243).
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for causes unrelated to lymphoma observed among patients treated
with R-FM compared with R-CVP.
Our results compare favorably with those of similar studies. In
the 83-month observation of the FL2000 study,15 the 8-year event-
free survival and OS rates were 44.1% and 78.6% for patients
randomly assigned to R-CHVP (cyclophosphamide, adriamycin,
vincristine, and prednisone) and interferon. In the OSHO#39 (East
German Study Group of Hematology and Oncology) study,16 after
a median follow-up of 102 months, the 8-year OS rate was 76.1%,
and the median event-free survival was 89.6 months for sur-
viving patients treated with R-MCP (rituximab plus mitoxantrone,
chlorambucil, and prednisolone). Finally, the 6-year update from the
PRIMA (Primary Rituximab and Maintenance) trial described a
6-year PFS rate of 42.7% and a favorable 6-year OS rate of 88.7% for
patients randomly assigned to the observation arm.17
With this update of the FOLL05 study, we contribute to the
definition of standard ICT in the initial treatment of patients with
advanced-stage FL. Our CSM data provide a better description of
the consequences of late events for patient survival, focusing on
life-threatening events and reducing the impact of curable con-
ditions that are also subject to under-reporting. Patients treated
with R-FM had high rates of SMs and a higher risk of dying as
a result of causes unrelated to lymphoma progression compared
with those receiving R-CVP.
The association between fludarabine-based regimens and SMs
has been already reported for NHLs.18-22 Sacchi et al23 described
a 12-year cumulative incidence rate of 10.5% for 563 patients with
indolent NHL enrolled in Gruppo Italiano Studio Linfomi trials
from 1988 to 2003. More recently, in a GELCAB (Grup d’Estudi
dels Linfomes de Catalunya i Balears) study, the 10-year risk of SM
was 8%, similar to what was found in our study,24 and the 10-year
rate was high (27%) in FND (fludarabine, mitoxantrone, and
dexamethasone) –treated patients, as reported by Nastoupil et al.25
Although the risk of SM is known with fludarabine combinations,
we should acknowledge that FCR (fludarabine, cyclophosphamide,
and rituximab) is well regarded as a highly effective and appropriate
regimen for patients with chronic lymphocytic lymphoma and is the
current standard against which other regimens are compared. With
increasing treatment efficacy, the problem of SM is suggested as
a relevant issue in FL and has been observed in other lymphoma
subtypes similarly treated with rituximab-containing regimens.26-28
In our initial report, we suggested that R-CHOP was a better
option than R-CVP. Considering the updated results, we conclude
with high confidence that patients treated with R-CHOP had
a lower risk of progressive disease than those treated with R-CVP.
In addition, our analysis of OS suggests that survival is similar
between R-CHOP and R-CVP. Regarding the OS data, however, it
should be emphasized that because of the small number of events,
these results are not sufficiently powered to draw definitive con-
clusions. In addition, the choice of salvage therapy in patients with
progressive disease was not defined in the protocol, and actually,
high heterogeneity among second-line therapies was seen (Table 2).
Our data suggest that patients initially treated with R-CVP main-
tained high chances of achieving second remission but also had
a 43% higher risk of requiring second-line treatment compared with
those receiving R-CHOP. In particular, when salvage treatment was
needed after R-CVP, this included R-CHOP in 26 patient cases (27%
of relapsed disease cases) or high-dose therapy in 27 patient cases
(28%). Moreover, if durable remission may translate into a so-called
cure of FL in a proportion of patients, we can also conclude that
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considering R-CHOP as initial therapy, patients have a higher
chance of being cured with the first course of therapy.
To put our results in perspective, we should acknowledge
some possible concerns. First, nomaintenance therapy was allowed
in the FOLL05 trial, and we were unable to estimate the effect of
prolonged use of rituximab in the comparison among study arms.
Even if it has been shown that the risk of progressive disease is
significantly reduced bymaintenance rituximab, no data are available
to suggest a different activity of maintenance between R-CHOP and
R-CVP. Moreover, considering that in the 6-year update of the
PRIMA trial, maintenance therapy did not result in any difference in
OS,17 we assume that our results might also be reproduced under the
conditions of maintenance therapy. Second, because the analysis of
late events is time dependent, and several events were reported after
salvage therapies, longer follow-up would be required.
Third, in recent years, the combination of BR (bendamustine
and rituximab) has been rapidly imposed as first-choice therapy
for patients with advanced-stage FL in need of treatment and is
now widely adopted.29,30 BR has been compared with R-CHOP or
R-CVP in two different trials, showing discordant results in favor of
higher antilymphoma activity of the new combination but also
showing strong evidence in favor of a better toxicity profile of
BR.27,31 Recently, long-term follow-up data from these studies have
been presented, confirming activity and safety data of the BR
combination; however, similarly to our study, differences in terms
of PFS did not translate into OS differences.32,33 Thus, given the
similar efficacy of BR versus R-CHOP, we believe they both rep-
resent the best available options to achieve long-lasting remissions
in patients with previously untreated FL. Further improvement is
expected with the adoption of maintenance therapy and with the
substitution of rituximab with the novel anti-CD20 agent obi-
notuzumab, which was recently shown to further reduce the risk of
progression.34
Finally, as ancillary results, we were also able to complete our
study with details on the histologically documented transformation
of FL into aggressive lymphoma. The observed transformation rate
was low compared with those in previous reports from retrospective
studies35-37 and similarly low compared with the 4.1% rate at 6 years
recently reported from the analysis of the PRIMA trial.38 Although
a formal and appropriate methodologic demonstration is lacking,
a protective effect of rituximab on the rate of transformation can
be suggested, as also recently reported by a large retrospective
international study.39
In conclusion, this long-term update of the FOLL05 trial
confirms the high efficacy of ICT for the initial treatment of
patients with advanced-stage FL in need of therapy. In addition,
with the longer follow-up, we can conclude that if the aim of
initial therapy is to maximize treatment activity and increase the
chance of durable disease control, R-CHOP should be the preferred
option among the three regimens. Conversely, R-CVP might be
seen as a good option in patients for whom the goal of therapy is
treatment tolerability; in this case, however, patients should be
informed about the higher probability of requiring second-line
treatment.
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